With its FDA approval, abemaciclib (Verzenio, Lilly) has risen to the top of the cyclin-dependent kinase (CDK) 4/6 inhibitor class of drugs for breast cancer, at least based on its unique indications, according to the agency.
“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine